¸ù¾ÝËÄ´¨Ê¡Ê³Æ·Ò©Æ·¼ìÑé¼ì²âÔº¡¶³ö¹ú£¨¾³£©½øÐÞÈËÔ±¹ÜÀíÔÝÐй涨¡·¼°È˲ÅÅàÑø¼Æ»®£¬Í¨¹ýȫԺ¹«¿ªÑ¡°ÎÓ빫ʾ£¬¾ËÄ´¨Ê¡Ò©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼£¬Ê¡ÔºÍÆÑ¡Ò©°ü²Ä¼ì²âÓëÒ©Æ·ÏàÈÝÐÔʵÑéÊҸ߼¶¹¤³ÌʦÆÑС´Ïͬ־ÓÚ2019Äê12ÔÂ31ÈÕÖÁ2020Äê12ÔÂ30ÈÕ¸°ÃÀ¹úÂíÀïÀ¼´óѧÅÁ¿Ë·ÖУ£¨UMD£©ÉúÎ﹤³Ìϵ½øÐÐÁËΪÆÚÒ»ÄêµÄ·ÃÎÊѧϰ¡£
ÆÑС´Ïͬ־ËùÔÚ¿ÎÌâ×éHuang LabµÄÑо¿ÖصãÊǶ԰©Ö¢¾«×¼ÖÎÁÆÄÉÃ×ҽѧµÄÑо¿¡£»ùÓÚ»úÖÆµÄÁªºÏÁÆ·¨µÄ¿ª·¢£¬°©Ö¢µÄ¹â¶¯Á¦ÁÆ·¨£¨PDT£©ÒÔ¼°Õë¶ÔÐԵĻúÖÆºÍ²ßÂÔÓ¦Óã¬ÌرðÊǶ¨µã¹â»¯Ñ§ºÍÓ«¹âÕï¶Ï¼¼Êõ¡£¿ÎÌâÉè¼ÆÁËÄÉÃ×¼¶µÄÁ£×Ó£¬¿ÉÒÔÔÚ·Ö×Ó¡¢Ï¸°ûºÍ΢»·¾³Ë®Æ½É϶ÔÖ×Áö½øÐйâѧºÍÉúÎïÎïÀí´¦Àí¡£ÕâÖÖ·½·¨¿ÉÒÔ´Ù½ø¶Ô»îÌ嶯ÎïºÍÁÙ´²ÊÔÑéÖÐÒ©ÎïÊäËÍ£¬ÃâÒßÄÍÊܺͷÖ×ÓÒ©ÎïÄÍÒ©ÐÔµÄÉúÀíÕϰµÄÑо¿¡£¸Ã¿ÎÌâ×éÓëÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨U.S. Food and Drug Administration£¬FDA£©¼°ÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº£¨National Institutes of Health£¬NIH£©µÈ»ú¹¹ÓÐ×ÅÃÜÇеĺÏ×÷¡£ÆÑС´Ïͬ־×÷ΪÖ÷ÑÐÈËÔ±Ö®Ò»²ÎÓëÁË¿ÎÌâ×éµÄ¸÷Ïî¿ÆÑС¢Ñ§Êõ¡¢½»Á÷»î¶¯£¬ÔÚ¿ÎÌâ×é»áÒéÉϽøÐÐÁËȫӢÎÄѧÊõ½»Á÷Ñݽ²£¬»ñµÃÁË¿ÎÌâ×éÒ»ÖÂºÃÆÀ£¬ÒÔ¹²Í¬×÷ÕßµÄÉí·ÝÍê³ÉÁËÂÛÎÄ¡°Ì½Ë÷¹ØÓÚPARPÒÖÖÆ¼Á°ÂÀÅÁÄáºÍ¹â¶¯Á¦ÖÎÁÆÁªºÏËù²úÉúµÄÞ׿¹×÷Óýø»¯¶¯Á¦Ñ§¡±£¨Exploiting the Evolutionary Dynamics of Resistance to Combination PARP Inhibitor Olaparib and Photodynamic Therapy£©µÄ׫д²¢²Î¼ÓÁË»ùÓÚʵÑéÊÒ°²È«·À»¤ºÍÒÇÆ÷ʹÓõĸ÷ÏîÅàѵ¡£
ͨ¹ýΪÆÚÒ»ÄêµÄ·ÃÎÊѧϰ£¬¸Ãͬ־ѧϰÁËÃÀ¹úÒ½Ò©¡¢ÎÀÉú¼°Ò½ÁÆÆ÷еµÈÁìÓò¶¥¼â¿ÆÑлú¹¹ÔÚҩеÑз¢¡¢¼ì²âÁìÓòÏȽø¡¢Ç°Ñصķ½·¨ºÍ¾ÑéÒÔ¼°¹úÍâÏȽøÊµÑéÊÒ¹ÜÀí¡¢ÔËÐÐģʽÓë¾Ñ飬½áʶÁ˲¿·Ö¹ú¼Òרҵ»ú¹¹µÄרҵ¼¼ÊõÈËÔ±£¬ÉîÈëÁ˽âÃÀ¹úҩе°²È«¼à¹Ü×éÖ¯ÌåϵµÄ¼Ü¹¹£¬·¨¹æ¡¢±ê×¼µÄÖÆ¶¨¼°ÊµÑéÊÒ¹ÜÀíÌåϵµÄÔËÐС£·ÃÎÊѧϰÆÚ¼äͨ¹ý¶ÔÊÀ½ç¶¥¼âÃûУºÍÒ½Ò©¡¢ÎÀÉú¼°Ò½ÁÆÆ÷еÁìÓò¶¥¼¶×¨Òµ»ú¹¹µÄ²Î¹Ûѧϰ£¬ÌáÉýÁËѧÊõˮƽ£¬ÍØÕ¹Á˹ú¼ÊÊÓÒ°¡£ÔÚ½»Á÷ÆÚ¼ä£¬Ïò¹úÍâͬÐÐչʾÁËʡԺ¼ìÑé¼ì²â¼¼ÊõºÍ¶ÔÍâºÏ×÷½»Á÷µÄÄÜÁ¦£¬ÎªÊ¡ÔºÔö½ø¹ú¼Ê½»Á÷´î½¨Á˾Ñé¹²Ïí¡¢ÖÇ»ÛÅöײµÄƽ̨¡£
´Ë´Î·Ãѧ£¬ÊÇʡԺ¶ÔÍâ½»Á÷ºÏ×÷ºÍÈ˲ÅÅàÑø³ÖÐø×ÝÉî·¢Õ¹µÄ³É¹ûÖ®Ò»£¬»ù±¾ÊµÏÖÁËÑ§Ï°Ç°ÑØ¼¼ÊõºÍÏȽø¾Ñé¡¢ÍØ¿íרҵ¼¼ÊõÈËÔ±ÑÛ½çÓëÊÓÒ°¡¢Õ¹Ê¾Ê¡ÔºÐÎÏóºÍÌáÉýÓ°ÏìÁ¦µÄÄ¿±ê£¬ÎªºóÐø¹ú¼ÊºÏ×÷½»Á÷µì¶¨ÁË»ù´¡£¬¶ÔÔºÄÚҩе¼ìÑé¼ì²â¹¤×÷ºÍ¿ÆÑй¤×÷²úÉúÁË»ý¼«Ó°Ïì£¬ÍÆ¶¯×ÅʡԺ¼ìÑé¼ì²âÊÂÒµ²»¶Ï·¢Õ¹¡£